JBM (Healthcare) Limited
2161.HK
Hong Kong Stock Exchange2.31
HKD
-0.04
- -
JBM (Healthcare) Limited
2161.HK
(Hong Kong Stock Exchange)
Recent
price
2.31
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- JBM (Healthcare) Limited is an investment holding company engaged in the development, manufacturing, sourcing, distribution and marketing of branded healthcare and wellness products principally in Hong Kong, Macau, Mainland China and other markets in the Asia Pacific region. The company operates through three main segments offering Branded Medicines, which include medicines with chemical compounds as active ingredients; Proprietary Chinese Medicines, comprising registered Chinese herbal medicines such as Po Chai Pills (a leading gastrointestinal remedy with 120 years of tradition), Tong Tai Chung Woodlok Oil, Flying Eagle Woodlock Oil and Shiling Oil; and Health and Wellness Products, which encompass supplements, medical consumables, non-pharmaceutical items, over-the-counter medicines, medicated and non-medicated solutions and diagnostic devices. Founded in 2020 and headquartered at Units 808-811, 8th Floor, C-Bons International Centre, 108 Wai Yip Street, Kwun Tong, Kowloon, Hong Kong, JBM targets consumers seeking self-care solutions for health and well-being across Asia. Recent major developments include the completion of a 90% acquisition of Tin Hee Tong Medicine Factory, Limited in April 2025 to expand its proprietary Chinese medicines portfolio with the iconic Tin Hee Pills brand and planned marketing revitalization; entry into a sale and purchase agreement in June 2025 to acquire the entire share capital of Kenford Medical Group Company Limited for HK$38 million; a connected transaction in November 2024 involving the sale of shares in Li Chung Shing Tong (Holdings) Limited by subsidiaries Po Chai Herbal and PCHT to Europharm for HK$46.23 million; and a 2025 Europharm License Agreement announced in October 2025 alongside positive profit alerts and interim dividend declarations for the six months ended 30 September 2025.